The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
- Ist Teil von
- The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2211023Titel-ID: cdi_proquest_journals_2737142100
- Format
- –
- Schlagworte
- Adverse events, Anticholesteremic Agents - administration & dosage, Anticholesteremic Agents - adverse effects, Anticholesteremic Agents - pharmacology, Anticholesteremic Agents - therapeutic use, Apolipoproteins, Arteriosclerosis, Atherosclerosis - drug therapy, Cardiology, Cardiology General, Cardiovascular disease, Cardiovascular diseases, Cardiovascular Diseases - drug therapy, Cholesterol, Clinical trials, Confidence intervals, Coronary Disease, Double-Blind Method, Double-blind studies, Ezetimibe - therapeutic use, Genetics, Genetics General, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Hypercholesterolemia - drug therapy, Kexin, Laboratories, Lipids, Lipoprotein(a) - analysis, Lipoprotein(a) - antagonists & inhibitors, Liver - drug effects, Liver - metabolism, Low density lipoprotein, Myocardial Infarction, PCSK9 Inhibitors - therapeutic use, Placebos, Proprotein convertases, Risk factors, RNA Therapeutics, RNA, Small Interfering - administration & dosage, RNA, Small Interfering - adverse effects, RNA, Small Interfering - pharmacology, RNA, Small Interfering - therapeutic use, siRNA, Statistical analysis, Subtilisin